Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Michael Krauthammer, Yong Kong, Antonella Bacchiocchi, et al.
Nature Genetics (2015) Vol. 47, Iss. 9, pp. 996-1002
Open Access | Times Cited: 381

Showing 1-25 of 381 citing articles:

RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu, Dwight V. Nissley, Frank McCormick
Cell (2017) Vol. 170, Iss. 1, pp. 17-33
Open Access | Times Cited: 1566
Melanoma
Dirk Schadendorf, Alexander C.J. van Akkooi, Carola Berking, et al.
The Lancet (2018) Vol. 392, Iss. 10151, pp. 971-984
Closed Access | Times Cited: 1228
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward, James S. Wilmott, Nicola Waddell, et al.
Nature (2017) Vol. 545, Iss. 7653, pp. 175-180
Open Access | Times Cited: 1196
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 5, pp. 603-615
Open Access | Times Cited: 899
From melanocytes to melanomas
A. Hunter Shain, Boris C. Bastian
Nature reviews. Cancer (2016) Vol. 16, Iss. 6, pp. 345-358
Closed Access | Times Cited: 762
Cutaneous melanoma: From pathogenesis to therapy (Review)
Giulia C. Leonardi, Luca Falzone, Rossella Salemi, et al.
International Journal of Oncology (2018)
Open Access | Times Cited: 533
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 10, pp. 1315-1327
Closed Access | Times Cited: 524
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 4, pp. 435-445
Closed Access | Times Cited: 433
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
David E. Elder, Boris C. Bastian, Ian A. Cree, et al.
Archives of Pathology & Laboratory Medicine (2020) Vol. 144, Iss. 4, pp. 500-522
Open Access | Times Cited: 367
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Robert J. Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Nature Cell Biology (2018) Vol. 20, Iss. 9, pp. 1064-1073
Open Access | Times Cited: 355
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann, Michael Gmachl, Jürgen Ramharter, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 142-157
Open Access | Times Cited: 329
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu‐Lieskovan, et al.
Nature (2018) Vol. 553, Iss. 7688, pp. 347-350
Open Access | Times Cited: 302
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Peter A. Johansson, Lauren G. Aoude, Karin Wadt, et al.
Oncotarget (2015) Vol. 7, Iss. 4, pp. 4624-4631
Open Access | Times Cited: 268
The NF1 somatic mutational landscape in sporadic human cancers
Charlotte Philpott, Hannah Tovell, Ian M. Frayling, et al.
Human Genomics (2017) Vol. 11, Iss. 1
Open Access | Times Cited: 261
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newell, Yan Kong, James S. Wilmott, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 253
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution
A. Hunter Shain, Nancy M. Joseph, Richard Yu, et al.
Cancer Cell (2018) Vol. 34, Iss. 1, pp. 45-55.e4
Open Access | Times Cited: 195
The NF1 gene in tumor syndromes and melanoma
Maija Kiuru, Klaus J. Busam
Laboratory Investigation (2017) Vol. 97, Iss. 2, pp. 146-157
Open Access | Times Cited: 180
Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy
Thomas Wiesner, Heinz Kutzner, Lorenzo Cerroni, et al.
Pathology (2016) Vol. 48, Iss. 2, pp. 113-131
Open Access | Times Cited: 179
Future perspectives in melanoma research
Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, et al.
Journal of Translational Medicine (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 177
Targeted Genomic Profiling of Acral Melanoma
Iwei Yeh, Eric Jorgenson, Ling Shen, et al.
JNCI Journal of the National Cancer Institute (2019) Vol. 111, Iss. 10, pp. 1068-1077
Open Access | Times Cited: 154
Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka, Ewa Bartnik, Michał Fiedorowicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4576-4576
Open Access | Times Cited: 144
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma
Reinhard Dummer, Keith T. Flaherty, Caroline Robert, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 36, pp. 4178-4188
Open Access | Times Cited: 136
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
European Journal of Cancer (2024) Vol. 204, pp. 114073-114073
Open Access | Times Cited: 15
The genomic landscape of cutaneous melanoma
Tongwu Zhang, Ken Dutton‐Regester, Kevin M. Brown, et al.
Pigment Cell & Melanoma Research (2016) Vol. 29, Iss. 3, pp. 266-283
Open Access | Times Cited: 156
Page 1 - Next Page

Scroll to top